These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3609475)

  • 1. Thrombogenicity of factor IX complex: in vivo investigation.
    Aronson DL; Menache D
    Dev Biol Stand; 1987; 67():149-55. PubMed ID: 3609475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC; Matts L; Eisele J; Czachur M; Saidi P
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract]   [Full Text] [Related]  

  • 7. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion.
    Aronson DL; Thomas DP
    Thromb Haemost; 1985 Dec; 54(4):866-70. PubMed ID: 3879019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.
    Giles AR; Nesheim ME; Hoogendoorn H; Tracy PB; Mann KG
    Blood; 1982 Feb; 59(2):401-7. PubMed ID: 7034817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of factor IX concentrates in mice.
    Magner A; Aronson D
    Dev Biol Stand; 1979; 44():185-8. PubMed ID: 544292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1976 Apr; 35(2):386-95. PubMed ID: 989639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
    Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
    McGlasson DL; Harroff HH; Sutton J; Dick E; Elston DM
    Clin Lab Sci; 2007; 20(2):99-105. PubMed ID: 17557708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assembly of the intrinsic factor X activating complex--interactions between factor IXa, factor VIIIa and phospholipid.
    van Dieijen G; van Rijn JL; Govers-Riemslag JW; Hemker HC; Rosing J
    Thromb Haemost; 1985 Jun; 53(3):396-400. PubMed ID: 3931288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo.
    Refino CJ; Himber J; Burcklen L; Moran P; Peek M; Suggett S; Devaux B; Kirchhofer D
    Thromb Haemost; 1999 Sep; 82(3):1188-95. PubMed ID: 10494786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
    Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.